Vericel Corporation
HealthcareNASDAQ:VCEL · NASDAQ Capital Market
-$1.11 today
Vol 0.36M · Avg 0.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.7%
avg -22.8%
ROIC
2.3%
avg -16.7%
ROA
3.4%
avg -12.3%
Analysis
ROE is currently the strongest return metric at 4.7% versus its period average of -22.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Dominick C. Colangelo | Chief Executive Officer, President & Director | $1.74M | — | 62 | $85,000.00 | 0.17% |
Michael Halpin | Chief Operating Officer | $913,869.00 | — | 64 | $16,080.00 | 0.03% |
Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer | $854,869.00 | — | 50 | $21,009.00 | 0.04% |
Jonathan Hopper FRCSEd. | Chief Medical Officer | $755,885.00 | — | 64 | $80,128.00 | 0.16% |
Sean C. Flynn | Chief Legal Officer | $740,669.00 | — | 52 | $85,000.00 | 0.17% |
Eric Burns | Vice President of Finance & Investor Relations | — | — | — | — | — |
Jonathan Siegal | Principal Accounting Officer, Vice President & Corporate Controller | — | — | — | $80,128.00 | 0.16% |
Mike Gilligan | Senior Vice President of Sales | — | — | — | — | — |
Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | — | — | — | — | — |
Roland DeAngelis | Chief Marketing Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
23
$5.01M
Net Sentiment
$5.01M
Net selling
Most Active
MCLAUGHLIN KEVIN F
5 transactions
1–10 of 23
Analysis
Insiders reported 0 buys worth $0.00 and 23 sells worth $5.01M over the last 12 months. That adds up to net selling of $5.01M. MCLAUGHLIN KEVIN F was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +1245.6% | +18.7% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +1245.6% over three years. Forward estimates point to Revenue at +18.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.03B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Mesoblast Limited
NASDAQ:MESO
$1.79B
uniQure N.V.
NASDAQ:QURE
$1.74B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
MannKind Corporation
NASDAQ:MNKD
$1.13B
Who manages VCEL?
Vericel Corporation (VCEL) lists 10 active executives. The top listed executive is Jonathan Hopper FRCSEd., Chief Medical Officer.
Are VCEL insiders buying or selling?
Recent insider activity shows net buying of $10.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.